138 related articles for article (PubMed ID: 17932809)
21. [Development of conditionally replicating oncolytic HSV vector--targeted gene therapy for sarcoma by oncolytic viruses].
Takahashi K; Yamamura H
Nihon Rinsho; 2006 Mar; 64 Suppl 3():326-33. PubMed ID: 16615493
[No Abstract] [Full Text] [Related]
22. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
Todo T
Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
[TBL] [Abstract][Full Text] [Related]
23. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
Bauzon M; Hermiston TW
Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
[TBL] [Abstract][Full Text] [Related]
24. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
25. Herpes simplex virus type 1 amplicon vectors for the infectious delivery and expression of genomic DNA loci.
Senior SL; Wade-Martins R
Curr Opin Mol Ther; 2005 Aug; 7(4):337-45. PubMed ID: 16121699
[TBL] [Abstract][Full Text] [Related]
26. Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.
Simpson GR; Coffin RS
Methods Mol Biol; 2009; 542():551-64. PubMed ID: 19565922
[TBL] [Abstract][Full Text] [Related]
27. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
28. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
29. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
30. Construction and production of recombinant herpes simplex virus vectors.
Goins WF; Krisky DM; Wechuck JB; Huang S; Glorioso JC
Methods Mol Biol; 2008; 433():97-113. PubMed ID: 18679619
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
32. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.
Ishino R; Kawase Y; Kitawaki T; Sugimoto N; Oku M; Uchida S; Imataki O; Matsuoka A; Taoka T; Kawakami K; van Kuppevelt TH; Todo T; Takaori-Kondo A; Kadowaki N
Mol Ther; 2021 Feb; 29(2):762-774. PubMed ID: 33038943
[TBL] [Abstract][Full Text] [Related]
34. Development and application of replication-incompetent HSV-1-based vectors.
Berto E; Bozac A; Marconi P
Gene Ther; 2005 Oct; 12 Suppl 1():S98-102. PubMed ID: 16231061
[TBL] [Abstract][Full Text] [Related]
35. Engineering HSV-1 vectors for gene therapy.
Goins WF; Huang S; Cohen JB; Glorioso JC
Methods Mol Biol; 2014; 1144():63-79. PubMed ID: 24671677
[TBL] [Abstract][Full Text] [Related]
36. Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
Boscheinen JB; Thomann S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Dörrie J; Schaft N; Bach C; Rohrhofer A; Werner-Klein M; Schmidt B; Schuster P
Front Immunol; 2019; 10():2. PubMed ID: 30723467
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Hum Cell; 2002 Sep; 15(3):151-9. PubMed ID: 12703545
[TBL] [Abstract][Full Text] [Related]
38. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy.
Yun CO
Curr Opin Mol Ther; 2008 Aug; 10(4):356-61. PubMed ID: 18683100
[TBL] [Abstract][Full Text] [Related]
39. Oncotarget Strategies For Herpes Simplex Virus-1.
Zhang L; Tatsuya T; Nishiyama Y
Curr Gene Ther; 2016; 16(2):130-43. PubMed ID: 27029942
[TBL] [Abstract][Full Text] [Related]
40. Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs.
Zhang KX; Matsui Y; Lee C; Osamu O; Skinner L; Wang J; So A; Rennie PS; Jia WW
Gene Ther; 2016 May; 23(5):460-8. PubMed ID: 26905370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]